About 3-ketodihydrosphingosine reductase
3-ketodihydrosphingosine reductase (KDSR) is a protein
from Homo sapiens identified by UniProt accession
Q06136, 332 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | 3-ketodihydrosphingosine reductase |
|---|
| UniProt accession | Q06136 |
|---|
| Gene | KDSR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 332 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (176)
Diseases linked to this target (Open Targets).
- erythrokeratodermia variabilis et progressiva 4 · score 0.75
- erythrokeratodermia variabilis · score 0.46
- blood platelet disease · score 0.37
- neurodegenerative disease · score 0.36
- head and neck squamous cell carcinoma · score 0.22
- chronic lymphocytic leukemia · score 0.19
- monocyte count · score 0.19
- pancreatic ductal adenocarcinoma · score 0.19
- clear cell renal carcinoma · score 0.18
- hepatocellular carcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q06136-F1 | alphafold | PREDICTED | 95.35 | — |
Amino-acid sequence (332 residues)
MLLLAAAFLV AFVLLLYMVS PLISPKPLAL PGAHVVVTGG SSGIGKCIAI ECYKQGAFIT LVARNEDKLL QAKKEIEMHS INDKQVVLCI SVDVSQDYNQ VENVIKQAQE KLGPVDMLVN CAGMAVSGKF EDLEVSTFER LMSINYLGSV YPSRAVITTM KERRVGRIVF VSSQAGQLGL FGFTAYSASK FAIRGLAEAL QMEVKPYNVY ITVAYPPDTD TPGFAEENRT KPLETRLISE TTSVCKPEQV AKQIVKDAIQ GNFNSSLGSD GYMLSALTCG MAPVTSITEG LQQVVTMGLF RTIALFYLGS FDSIVRRCMM QREKSENADK TA
Explore 3-ketodihydrosphingosine reductase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets